Guided Therapeutics Inc (QB) (GTHP) 銘柄情報

Consecutive 8th thanksgiving, when there’s absolutely nothing to be thankful for here.
All indications are pointing to US clinical trials will not complete by 2024-end.
Guided management had 1 & 1 job only & that job was to ensure that SMI pays them in full & on time as per contractual obligations. Did they do their job? No, they didn’t. In spite of not doing their job, they keep on rewarding themselves dividend stocks & other kind of stock payments. Why?
When they know that SMI is neither paying them in full nor paying them on time, still why do they keep on partnering with a non trustworthy partner at the expense of stockholders’ losses? Why?
Let’s see if SMI pays them 1.34 ML$ by 2024 end.
Stock is illiquid & if it trades then there are only sells & more sells & even more sells.
Bid stubbornly sits at 0.16$ & never goes up. Every slightest uptick in the bid price is immediately taken & heavy selling resumes. There’s absolutely no buying support for the stock because management is not doing their jobs.
Stockholders suffered 99% losses on their investment in this company’s stock solely because of incompetent-at-best, inept-at-worst, lazy, no-performance, no-capability, grossly overpaid executives management.

SMI did all that on their own?

Wow! Guided sure was lucky to find SMI.

You realize, I assume, that SMI can't sell the device in China without buying the device from Guided. If the NMPA approves the device, that's a huge win for Guided -- getting a 400-patient clinical trial completed and getting NMPA approval would have been very expensive otherwise.

"Shame on you" indeed.

SMI completed Chinese clinical trial on its own. SMI submitted to NMPA on its own. In this where exactly is GTHP management’s so-called performance?
In SMI saga, the only job GTHP management had was to ensure that SMI pays to GTHP on-time & in-full. They completely & miserably failed to do their job. When they knew the 1st time that SMI isn’t paying them on-time & in full & hence can no longer be trusted they were supposed to find an another paying & trustworthy partner in China. They say, fool me once shame on you, fool me twice shame on me. SMI made a complete fool out of GTHP management not only once or twice but thrice now & yet GTHP management continues to partner with them at the expense of stockholders’s losses. In spite of GTHP management’s miserably failed performance, they continue to reward themselves dividend stocks & all kind of other stock payments. What a disgraceful, shameful, pathetic, selfish & despicable behaviour.
They were supposed to complete US clinical trials by 2024-end. All indications are pointing to that deadline will be missed. Till date GTHP management hasn’t achieved a single one self-published deadline for any task “ever”.
They are incompetent-at-best, inept-at-worst, lazy, no-performance, no-capability, grossly overpaid executives.

LOL do you think Faupel and Blumberg would disclose there were non payments. Now that is funny!

Stock is t traded at all. Even if it trades then there are only sells, more sells & even more sells. There are 206K stock available for sale at the bargain basement price of 0.185$ & there are absolutely no buyers at all. The incompetent, inept, lazy no-performance & no-capability management is solely responsible for this situation. They have completely & miserably failed to do their job.

SMI got a large clinical trial completed and SMI submitted an application to the Chinese FDA, all at basically no cost to Guided Therapeutics.

You wish that Guided Therapeutics had stayed with Shenghuo?

The latest 10-Q states following

Forty-seven (47) of the 100 IPs will be provided by GTI to SMI, at an approximate price of $1,351,250; The number of IPs may be reduced if the full payment is delayed beyond the end of 2024.

If anyone believes that SMI will pay GTHP $1,351,250 by end of 2024, then they are delusional. SMI didn’t pay GTHP 200K$, then SMI didn’t pay GTHP 700K$ at the time of filing to NMPA. SMI had defaulted on their each & every contactual payment obligations till date. What makes GTHP management think that SMI will pay them $1,351,250 by end of 2024? In spite of SMI defaulting, why GTHP management keep on partnering with them? What are GTHP management’s vested interests in continuing partnership with full payment defaulting entity such as SMI? What did SMI do to GTHP management so as to deserve such extraordinary special treatment?

That's not what the 10-Q says. Not even close.

Read it again. Might help. Probably not.

Look at the latest 10-Q. Till now only 255 patients are completed. So US clinical trials “‘may” complete by June-end 2025. Absolutely no news about SMI owing GTHP almost 1ML$.
The incompetent-at-worst, inept-at-best, no-performance, no-capability management of this company failed miserably & completely to do their job in ensuring that SMI pays their contractual obligations in full. In spite of them completely failing to do their job, they are still paying themselves dividend stocks & other form of stock payments at the expense of shareholders’ losses.
It’s because of them stock’s bid stubbornly sits at 0.15-0.16$ & doesn’t go up. It’s because of them ask keeps on precipitously going down & down & more down. It’s because of them stock has become illiquid & if at all it trades there are only sells & more sells & even more sells. It’s because of them many broker-dealers/market-makers exploit the opportunities to manipulate the stock price.

It appears that GTSM is again trying to manipulate the stock price.
The incompetent-at-worst, inept-at-best, no-performance, no-capability management of this company is supposed to publish the latest 10-Q today. However considering the state in which management brought this company in, it’s irrelevant & immaterial at this stage whether they publish latest 10-Q or not.
It appears that management of this company failed miserably & completely to do their job in ensuring that SMI pays their contractual obligations in full at the time of NMPA filing. In spite of them completely failing to do their job, they are still paying themselves dividend stocks & other form of stock payments at the expense of shareholders’ losses.
Hopefully US clinical trials are still on track to be completed by this year end.

Don’t know if there’s any slightest ray of light at the end of dark tunnel. Stock is illiquid & if it trades then there are sells & more sells. This company is run by incompetent-at-worst, inept-at-best, no-performance, no-capability management. A technologically great product having innovative ground-breaking product is in the hands of incompetent, inept & lazy people. They only know how to enrich themselves at the expense of stockholders’ losses.

In September, you said the price would never go above 12 cents, and then you said it would never go above 15 cents.

In October, you said the price would never go above 16 cents.

Now it's November and you're saying the price will never go above 21 cents.

Thanks for the weather report.

370K stock available for sell at 0.21$. Highly doubt that this stock will go above 0.21$

NITE broker-dealer/market-maker is manipulating the security price now.

70K stock sell around 0.15$.
Long stockholders, how do you feel about this?
There are sells, sells & more sells. Long stockholders, they just want to get out of their long positions at any bargain basement salvage price they can get.

60K stock was bought at 0.16$ & yet NITE’s 34475 stock available at sale 0.16$ didn’t move at all. This is a clear evidence that NITE along with GTSM & CFGN broker-dealers/market-makers are actively involved in stock price manipulation.

Yesterday was odd. Wonder if news is coming out.

The US clinical trials won't finish until end of year at the EARLIEST, so it probably wouldn't be about that. Q3 Financials, meh, the NMPA submission was Q4 so any payments won't be on the books in Q3....

Possibly a PR About SMI payments? I, for one, don't think SMI has much money, but at least they got the NMPA application submitted.

Here is some interesting reading about the NMPA's proposed changes to their existing Medical Device Regulation (MDR, aka Order 739). The first one doesn't apply to the LuViva Scan but the second one does:
* Under the existing Medical Device Regulation (MDR, also known as Order 739), an imported medical device must be approved in the country of origin before it can be approved in China, unless the product at issue is an innovative device. The draft MDAL proposes to remove this requirement for country-of-origin approval (Article 47). An imported medical device can undergo the regulatory review and approval process in China in parallel to the same in other countries and shorten the time to market in China.

* Marketing authorizations of medical devices, unlike drugs, cannot be transferred between different entities under the Order 739. The draft MDAL explicitly states that marketing authorizations can be assigned and the NMPA will issue specific implementing measures (Article 58). R&D-based medical device companies can sell the right to their products along with the marketing authorizations in the form of an asset sale.

https://www.ropesgray.com/en/insights/viewpoints/102ji2j/chinas-nmpa-requests-public-comments-on-its-first-medical-device-law-three-key

I say ther first one doesn't apply to the LuViva Scan because it's an "innovative device." At least, the Chinese doctors called it "innovative:"

https://www.biospace.com/leading-cervical-cancer-doctors-support-approval-of-luviva-in-china-based-on-preliminary-review-of-clinical-trial-results
According to Dr. Sui, “We are eager to complete the validation of this innovative technology and submit an application to the NMPA, and we are confident that LuViva will represent the next generation of early cervical cancer detection technology, with its advantages of accuracy, ease of use and immediate results.”

You don't seem to understand what "Safe Harbor" means or why it is used.

Perhaps funds and ETF's are better suited to your investment needs and knowledge.

This company’s management publicly stated in 1 of their 10-Qs that they will arrange/facilitate a loan of 200K$ for SMI & book that as revenue with SMI being on the hook to pay back all the loan along with all charges associated with the loan arrangement/facilitation.
But that’s a “safe harbor “ statement!

This company’s management publicly stated in 1 of their 10-Qs that when SMI will file for NMPA at that time SMI will pay 700K$ to GTHP as per their contractual obligations.
But that’s a “safe harbor” statement as well.

In recent PR, this company’s management publicly stated that The filing with NMPA triggers the continuation of the working relationship between the Company and SMI, with milestones and minimum payments to GTI for devices, disposables, services and royalties of more than $125 million over the next six years.
But that’s a “safe harbor “ statement as well.

Does this company’s management gets paid to put out “safe harbor “ statements or generating revenue & net income?

"Materially misleading?"

You don't know what "Safe Harbor" means?

Well then. You're going to have a difficult time deciding which class action to pursue. And don't limit yourself to GTHP because every stock on every exchange issues materially misleading press releases by your definition.

You and myjob should get together and burn pictures of GTHP Officers in effigy.

Any publicly traded company’s management’s performance is tied to the revenue & net-income they generate. If GTHP management is not able to ensure that SMI pays & pays them in full & on time then is GTHP management doing their job? Why should stockholders suffer losses for GTHP management’s non-performance? Why GTHP management deserve dividend stocks when they are not generating any revenue from their business partner in China? Why GTHP management deserves a sweetened deal to acquire stock at 0.12$ when in open market the stock is traded around 0.16$?

Looks Like Myjob' s last post does clarify they are looking to know if the 700k payment was not made, partially made, or made in full.

In my opinion the Press Release touting $125 million in future payments from a inadequately financially performing (not making full contractual payments in the past and possibly currently) Chinese partner is materially misleading to all.

Me tooooo

This company’s management need to clearly inform stockholders about following:
1) In 1 of their 10-Qs they stated that they will arrange/facilitate a loan of 200K$ for SMI & book that as revenue with SMI being on the hook to pay back all the loan along with all charges associated with the loan arrangement/facilitation. What happened to that?
2) In 1 of their 10-Qs they stated that when SMI will file for NMPA at that time SMI will pay 700K$ to GTHP as per their contractual obligations. Did SMI pay GTHP 700K$? What happened to that?

& most importantly if SMI neither took that 200K$ loan nor SMI paid 700K$ to GTHP then did GTHP management “lie” on their 10-Q?
SMI has a history of not-fully-paying then why GTHP management continue to do business / partnership with a non-full-paying & non-trustworthy partner? What are GTHP management’s vested interests in continuing partnership with a non-full-paying & non-trustworthy partner?
Did SMI pay any “bribes” to GTHP management so that GTHP management keeps on giving chances after chances to a non-full-paying & non-trustworthy partner? Why GTHP management not make a genuine efforts to have an alternative to SMI who’s fully-paying & trustworthy?

saw it once before -- June 8, 2023. It fell as low as .062 on a 651,700 volume day. I got some that day, but not enough.

I hope this seller gets desperate like THAT seller, because I know two people who will be buying: me, and myjog

Wow over 300,000 shares to dump never see this before. If they dump at market price will drop to 0001 at no time

As I understand it only requires ONE SHAREHOLDER to bring that type of law suit.

Perhaps such a suit would bring Gene Cartwright into it?

That happened in 2017 and it was disclosed. I don't see any kind of class action arising from that.

And I can't do it -- I didn't own GTHP in 2017 so I wouldn't be in that class. I've been in and out of GTHP since 2015 but I was out for all of 2017 so I can't help you, sorry.

But let us know how that works out.

RED FLAG GTHP DIRECTORS EFFECTIVELY WAIVED CONFLICT OF INTEREST PROVISIONS OF GTHP'S CODE OF ETHICS

Sounds like a breach of fiduciary duty to me perhaps a shareholder of GTHP will bring a derivative (class action type) law suit on the same?

Best of luck with that.

Ask them, I can only make reasonable inferences.

I believe it would be called a shareholder derivative claim (type of class action) where a shareholder on behalf of the Company GTHP (and its shareholders) sues any officer or director for breach of fiduciary duty by said officer or director.

That's not what myjob is complaining about.

The company said ""The filing with NMPA triggers the continuation of the working relationship between the Company and SMI." Direct quote. That is a true statement. Myjob is claiming the company is lying to try and manipulate the stock price down. The stock price is too high for myjob and THAT is what he's complaining about.

The plaintiff filed for an appeal in September.

I don't see any reason why an appeal would go any differently. Judges are human and make mistakes, but so are plaintiffs. Just because a plaintiff says the defendant is guilty doesn't mean the defendant is guilty.

For example, the plaintiff in this case we're discussing is the defendant in a different case where a former client named Manoloules is accusing him of malpractice. Just because THAT plaintiff claims malpractice doesn't mean there was malpractice, and if Manoloules loses and files for an appeal, THAT doesn't mean the defendant is guilty of malpractice.

None of which matters. My opinion remains that you should file a lawsuit for your "Unethical Conduct" accusation instead of complaining about it on a stock message board.

If the payment was made in full I am sure they would be mentioning it thus it is reasonable to assume that it was not made and they are not disclosing that is what I infer Myjob is complaining about.

Yes but they don't have to disclose every payment.

Its not over until the fat lady sings I believe is the saying?

Did the appeals period end? Was an appeal filed?

Judges are human and make mistakes too!

I was replying to Myjog post 15713 where he says the press release did not disclose whether the $700k was paid to GTHP.

Give you three guesses as to who just put up that 300k for sale.

Hint: who just lost his lawsuit against Shenghuo Medical LLC and now probably has to pay Shenghuo's Attorney fees and costs?

If we're lucky, he'll get impatient and drop his ask below a dime.

300K stock available for sale at 0.165$ from Citadel. Does anyone have any doubts that this stock will go above 0.165$ ever?

Calling management "liar" is libel unless you have proof. How and when did they lie?

I don't think they lied. It is what it is. The company doesn't have to disclose payments -- a payment is not a material event.

Nobody believes that SMI will pay $125 million over the next six years.

"The filing with NMPA triggers the continuation of the working relationship between the Company and SMI" is a true statement. What's your objection to that statement? They've re-written the SMI agreement every time SMI misses a payment and it's going to happen again. You're overlooking the most important part of the story: the application was submitted to the NMPA. Guided Therapeutics could not have done that without SMI. Guided could not have completed the Chinese clinical trial without SMI. This PR is good news no matter how much you try to spin it otherwise.

Maybe you need to raise your bid -- I don't think you're going to get any more under a dime no matter how much you bash.

Take them to court then. Don't waste your time complaining here.

Hope you have better luck than Paul Conte. He lost in his lawsuit against Blumberg and Faupel et al.

What "material fact" did they not disclose?

Unethical Conduct of Management RED FLAG Reposting

Perhaps GTHP shareholders should bring a Law Suit against Faupel and Blumberg.
RED FLAG GTHP DIRECTORS EFFECTIVELY WAIVED CONFLICT OF INTEREST PROVISIONS OF GTHP'S CODE OF ETHICS
THIS SOUNDS LIKE TURNING A BLIND EYE TO UNETHICAL - CONFLICT OF INTEREST BEHAVIOR BY FAUPEL AND BLUMBERG

What is MOST INTERESTING about GETS posting of 8k item is that in referencing the fee splitting agreement is: GTHP (disinterested Directors "effectively waived the conflict-of-interest provisions of the Company’s code of ethics." "On January 15, 2017, each of the disinterested directors on the Company’s Board of Directors, having considered the interests of Dr. Faupel and Mr. Blumberg and having approved the agreement, effectively waived the conflict-of-interest provisions of the Company’s code of ethics." THIS LOOKS LIKE A RED FLAG TO ME

I will again say that Shenghou LLC the original License Agreement Holder was a sham transaction, as Shenghou did not have the expertise to fulfill its obligation under the same, and perhaps it is a self directed dealing of GTHP assets - Splitting GTHP fees to insiders Faupel and Blumberg who are owners in Shenghou., LLC. and perhaps GTHP effectively waived its conflict of interests code to allow Faupel and Blumberg to receive compensation at the expense of the shareholders of GTHP, without having to disclose this as compensation to these two insiders at GTHP. I would call this turning a blind eye.

Non Disclosure of Material Facts = Fraud in some States!

Today as per PR, it appears that SMI filed for NMPA. In spite of such a (supposedly) slightly good news, if anyone is wondering why stock didn’t go up? It’s because the liar management of this company is not saying a word about whether or not SMI paid them 700K$ when they filed for NMPA in this PR as per their contractual obligations as stated by this company in 1 of their 10-Qs.
The reason stock’s not going up because absolutely no one believes the liar management of this company when they state the following : The filing with NMPA triggers the continuation of the working relationship between the Company and SMI, with milestones and minimum payments to GTI for devices, disposables, services and royalties of more than $125 million over the next six years.
—————-
125 ML$ for next 6 years, are you kidding me? When SMI couldn’t pay them 200K$ then one must be a delusional to believe that SMI will give a 125 ML$ business to GTHP in next 6 years, forget about actual payments.

Guided Therapeutics Announces Filing of Application for NMPA Approval to Market and Sell LuViva in China

Very sorry & sad state of affairs for this stock. Shorts have increased in the month of September & there’s absolutely neither any buying nor any buying support for the stock.
Incompetent inept lazy dishonest & fraudulent management is solely responsible for stock not trading & if it trades then there are only sellers of the stock who are ready to sell the stock at any bargain basement salvage price they can get.
Bid is not going up at all but ask keeps on going down & down & even more down.

There are absolutely no buyers & no buying support for the stock at-the-moment.

Take a look at latest 8K.

Does any long stockholder think that investing in this company is the worst investment mistake you have ever made?

For the last 7+ years 99% of loss for long stockholders.

In 1 of the 10-Qs the management of this company stated that they will facilitate a 200K$ loan for SMI & then book that as revenue. No word from this company about that.

In 1 of the 10-Qs the management of this company stated that when (& if) SMI files for NMPA, they will pay GTHP around 700K$. Till date there’s no word about any of that.

SMI has proven to be non-paying & non-trustworthy & yet the management of this company continue to partner with them. Why?